{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:08:07Z","timestamp":1789945687449,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.euf.2016.11.011","type":"journal-article","created":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T00:16:05Z","timestamp":1481588165000},"page":"502-509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma"],"prefix":"10.1016","volume":"3","author":[{"given":"Stephanie L.","family":"Skala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Udager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon Z.","family":"Weizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh S.","family":"Palapattu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Fields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed E.","family":"Abugharib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moaaz","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled S.","family":"Hafez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajjai","family":"Alva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arul M.","family":"Chinnaiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2016.11.011_bib0005","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euf.2016.11.011_bib0010","series-title":"WHO Classification of Tumours of the Urinary System and Male Genital Organs","author":"Moch","year":"2016"},{"key":"10.1016\/j.euf.2016.11.011_bib0015","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.eururo.2015.06.044","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 update","volume":"68","author":"Roupret","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2016.11.011_bib0020","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2016.11.011_bib0025","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1464-410X.2010.09675.x","article-title":"Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005","volume":"107","author":"Raman","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2016.11.011_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.02.010","article-title":"Effect of concomitant variant histology on the prognosis of patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy","volume":"33","author":"Shibing","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2016.11.011_bib0035","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2012.02.030","article-title":"Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature","volume":"62","author":"Lughezzani","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2016.11.011_bib0040","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ctrv.2015.02.006","article-title":"A contemporary review of management and prognostic factors of upper tract urothelial carcinoma","volume":"41","author":"Leow","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euf.2016.11.011_bib0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nrc3880","article-title":"Immunotherapy: checkpoint parley","volume":"15","author":"Bordon","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euf.2016.11.011_bib0050","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.cell.2015.08.038","article-title":"Releasing the brakes on cancer immunotherapy","volume":"162","author":"Littman","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.euf.2016.11.011_bib0055","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2016.11.011_bib0060","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2016.11.011_bib0065","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2016.11.011_bib0070","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous nonsmall-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2016.11.011_bib0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell nonsmall-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2016.11.011_bib0080","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2016.11.011_bib0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.euf.2016.11.011_bib0090","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2016.11.011_bib0095","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2016.11.011_bib0100","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2016.11.011_bib0105","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","article-title":"Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers","volume":"56","author":"Nakanishi","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.euf.2016.11.011_bib0110","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1158\/1078-0432.CCR-08-0731","article-title":"T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival","volume":"14","author":"Boorjian","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2016.11.011_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2014.10.020","article-title":"Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma","volume":"85","author":"Faraj","year":"2015","journal-title":"Urology"},{"issue":"9","key":"10.1016\/j.euf.2016.11.011_bib0120","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","article-title":"Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches","volume":"27","author":"Udager","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2016.11.011_bib0125","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.euf.2015.03.004","article-title":"Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy in urothelial carcinoma","volume":"1","author":"McDaniel","year":"2016","journal-title":"Eur Urol Focus"},{"issue":"9","key":"10.1016\/j.euf.2016.11.011_bib0130","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/annonc\/mdw268","article-title":"PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?","volume":"27","author":"Al-Ahmadie","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2016.11.011_bib0135","doi-asserted-by":"crossref","first-page":"e0136023","DOI":"10.1371\/journal.pone.0136023","article-title":"PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups","volume":"10","author":"Schmidt","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.euf.2016.11.011_bib0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.acthis.2006.01.003","article-title":"Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance","volume":"108","author":"Wu","year":"2006","journal-title":"Acta Histochem"},{"key":"10.1016\/j.euf.2016.11.011_bib0145","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2217\/fon.15.337","article-title":"The PD-1\/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target","volume":"12","author":"Bardoli","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.euf.2016.11.011_bib0150","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456916301699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456916301699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:46:03Z","timestamp":1762497963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456916301699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":30,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S2405456916301699"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2016.11.011","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2016.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}